Binds Lymphocytic Or Lymphocytic-like Cell Or Component Or Product Thereof (e.g., B Cell, B-lineage Bone Marrow Cell, Null Cell, Natural Killer Cell, B-lymphoblastoid Cell, B-lineage Acute Lymphoblastic Leukemia Cell, B-lymphocytic Cell-surface Antigen, Etc.) Patents (Class 530/388.73)
Binds t-lymphocytic cell or component or product thereof (e.g., t cell, thymocyte, t-lineage bone marrow cell, t-lymphoblastoid cell, t-lineage acute lymphoblastic leukemia cell, t-lymphocytic cell-surface antigen, etc.) (Class 530/388.75)
  • Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
    Patent number: 6251395
    Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: June 26, 2001
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
    Patent number: 6228360
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: May 8, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Man Sung Co, Maximiliano Vasquez
  • Method for increasing mean survival times of transplants with LFA-1-specific antibodies
    Patent number: 6214342
    Abstract: Mean survival times of a functional transplant of solid organs in a patient are increased by administering to the patient an initial dosing of a therapeutically effective amounts of a monoclonal antibody directed against the human LFA-1 molecule in the two hours after grafting and then administering daily dosing during a period of approximately nine days.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: April 10, 2001
    Assignee: Imtix-Sangstat
    Inventors: Gilles Alberici, Pierre Caudrelier, Brigitte Le Mauff, Maryvonne Hourmant, Jean-Paul Soulillou
  • Humanized antibodies reactive with L-selectin
    Patent number: 6210671
    Abstract: Humanized immunoglobulins specifically reactive with L-selectin are prepared employing recombinant DNA technology for use in e.g., treatment of inflammatory disorders.
    Type: Grant
    Filed: December 27, 1995
    Date of Patent: April 3, 2001
    Assignee: Protein Design Labs, Inc.
    Inventor: Man Sung Co
  • Specific antibodies and antibody fragments
    Patent number: 6207156
    Abstract: The present invention relates to methods and products for immunotherapy resulting in the stimulation of T-cell proliferation. The products of the invention are peptides that bind to CTLA-4 and co-stimulate the proliferation of T-cells by inhibiting the binding of B7 to CTLA-4. Pharmaceutical compositions including such peptides are also provided. The invention further provides in vitro and in vivo therapeutic methods employing the peptides of the invention.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: March 27, 2001
    Assignee: Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. Kuchroo, Edward A. Greenfield
  • Monoclonal antibodies against leukocyte adhesion receptor &bgr;-chain, methods of producing these antibodies and use therefor
    Patent number: 6187308
    Abstract: Monoclonal antibodies and method for ameliorating an immune response disorder. The monoclonal antibodies are specific for an epitope present on the leukocyte adhesion receptor &bgr;-chain.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: February 13, 2001
    Assignee: The Johns Hopkins University School of Medicine
    Inventor: James E. Hildreth
  • Cloning and uses of the genetic locus BCL-6
    Patent number: 6174997
    Abstract: This invention provides an isolated vertebrate nucleic acid molecule the bcl-6 locus. This invention also provides an isolated human nucleic acid molecule of bcl-6 locus. This invention further provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of bcl-6 locus. This invention provides an isolated vertebrate nucleic acid molecule of bcl-6 operatively linked to a promoter of RNA transcription. This invention provides a vector which comprises the nucleic acid molecule of bcl-6 locus. This invention provides a host vector system for the production of a polypeptide encoded by bcl-6 locus, which comprises the vector of bcl-6 locus in a suitable host. This invention provides a polypeptide encoded by the isolated vertebrate nucleic acid molecule of bcl-6 locus. This invention provides an antibody capable of binding to polypeptide encoded by bcl-6 locus.
    Type: Grant
    Filed: March 15, 1999
    Date of Patent: January 16, 2001
    Assignees: The Trustees of Columbia University in the City of New York, Sloan-Kettering Institute for Cancer Research
    Inventors: Raju S. K. Chaganti, Riccardo Dalla-Favera
  • Anti-IgE antibodies and method of improving polypeptides
    Patent number: 6172213
    Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
    Type: Grant
    Filed: June 30, 1998
    Date of Patent: January 9, 2001
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe